These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 20951927)

  • 1. Pharmabiotic manipulation of the microbiota in gastrointestinal disorders, from rationale to reality.
    Shanahan F; Collins SM
    Gastroenterol Clin North Am; 2010 Sep; 39(3):721-6. PubMed ID: 20951927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical evaluation of probiotic activity of lactic acid bacteria and their effects.
    Heczko PB; Strus M; Kochan P
    J Physiol Pharmacol; 2006 Nov; 57 Suppl 9():5-12. PubMed ID: 17242483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Probiotics in functional gastrointestinal disorders: what are the facts?
    Quigley EM
    Curr Opin Pharmacol; 2008 Dec; 8(6):704-8. PubMed ID: 18775516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Probiotics and inflammatory bowel disease: from fads and fantasy to facts and future.
    Shanahan F
    Br J Nutr; 2002 Sep; 88 Suppl 1():S5-9. PubMed ID: 12215176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Probiotics in inflammatory bowel disease--therapeutic rationale and role.
    Shanahan F
    Adv Drug Deliv Rev; 2004 Apr; 56(6):809-18. PubMed ID: 15063591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials.
    Hedin C; Whelan K; Lindsay JO
    Proc Nutr Soc; 2007 Aug; 66(3):307-15. PubMed ID: 17637082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Probiotics for inflammatory bowel disease: a critical appraisal.
    Sans M
    Dig Dis; 2009; 27 Suppl 1():111-4. PubMed ID: 20203506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Probiotics and gastrointestinal diseases.
    Sullivan A; Nord CE
    J Intern Med; 2005 Jan; 257(1):78-92. PubMed ID: 15606379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bacteria: a new player in gastrointestinal motility disorders--infections, bacterial overgrowth, and probiotics.
    Quigley EM
    Gastroenterol Clin North Am; 2007 Sep; 36(3):735-48, xi. PubMed ID: 17950446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Probiotics: which and when?
    Scarpellini E; Cazzato A; Lauritano C; Gabrielli M; Lupascu A; Gerardino L; Abenavoli L; Petruzzellis C; Gasbarrini G; Gasbarrini A
    Dig Dis; 2008; 26(2):175-82. PubMed ID: 18431068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Probiotics: use in allergic disorders: a Nutrition, Allergy, Mucosal Immunology, and Intestinal Microbiota (NAMI) Research Group Report.
    Isolauri E; Salminen S;
    J Clin Gastroenterol; 2008 Jul; 42 Suppl 2():S91-6. PubMed ID: 18542035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Probiotics in transition.
    Shanahan F; Dinan TG; Ross P; Hill C
    Clin Gastroenterol Hepatol; 2012 Nov; 10(11):1220-4. PubMed ID: 23010563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota.
    Kajander K; Myllyluoma E; Rajilić-Stojanović M; Kyrönpalo S; Rasmussen M; Järvenpää S; Zoetendal EG; de Vos WM; Vapaatalo H; Korpela R
    Aliment Pharmacol Ther; 2008 Jan; 27(1):48-57. PubMed ID: 17919270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical usefulness of probiotics in inflammatory bowel diseases.
    Mach T
    J Physiol Pharmacol; 2006 Nov; 57 Suppl 9():23-33. PubMed ID: 17242485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammatory bowel disease: current insights into pathogenesis and new therapeutic options; probiotics, prebiotics and synbiotics.
    Geier MS; Butler RN; Howarth GS
    Int J Food Microbiol; 2007 Apr; 115(1):1-11. PubMed ID: 17137666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Probiotics and irritable bowel syndrome: rationale and clinical evidence for their use.
    Barbara G; Stanghellini V; Cremon C; De Giorgio R; Gargano L; Cogliandro R; Pallotti F; Corinaldesi R
    J Clin Gastroenterol; 2008 Sep; 42 Suppl 3 Pt 2():S214-7. PubMed ID: 18685517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date.
    Quigley EM; Flourie B
    Neurogastroenterol Motil; 2007 Mar; 19(3):166-72. PubMed ID: 17300285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale for probiotic treatment strategies in inflammatory bowel disease.
    Schultz M; Lindström AL
    Expert Rev Gastroenterol Hepatol; 2008 Jun; 2(3):337-55. PubMed ID: 19072384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical indications for probiotics: an overview.
    Goldin BR; Gorbach SL
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S96-100; discussion S144-51. PubMed ID: 18181732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intestinal colonisation, microbiota and future probiotics?
    Salminen S; Benno Y; de Vos W
    Asia Pac J Clin Nutr; 2006; 15(4):558-62. PubMed ID: 17077076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.